Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, which evaluated icotrokinra, an oral peptide, in treating plaque psoriasis ... or hands and feet), with ...

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis, according to results from the ICONIC-TOTAL study.

Icotrokinra led to high rates of skin clearance in patients with scalp and genital psoriasis ... plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and soles of the feet.